

Oral cholera vaccines in mass immunization campaigns

GUIDANCE FOR PLANNING AND USE



Oral cholera vaccines in mass immunization campaigns GUIDANCE FOR PLANNING AND USE



WHO Library Cataloguing-in-Publication Data

Oral cholera vaccines in mass immunization campaigns: guidance for planning and use.

1.Cholera – immunology. 2.Cholera vaccines. 3.Mass immunization. I.World Health Organization.

ISBN 978 92 4 150043 2 (NLM classification: WC 262)

For further information, please contact the Global Task Force on Cholera Control **cholera@who.int** or visit our web site at **www.who.int/cholera**.

For a real life experience of a cholera mass vaccination campaign please view the WHO video "Oral cholera vaccines: a mass vaccination campaign, Zanzibar, United Republic of Tanzania, 2009" at http:// www.who.int/cholera/technical/prevention/vaccines/en/index. html

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by minimum graphics Printed in France

Contents

1.	Back	groun	d	1	
	1.1	Introd	luction	1	
	1.2 The disease: causative agent, clinical manifestations,				
		prevention .3 Risk factors, seasonality and vulnerable groups			
	1.3				
	1.4 Usually-recommended prevention and control measure				
		other	than vaccines	4	
2.	Chol	era va	ccines: general considerations	6	
	2.1	Intern	ationally-licensed vaccines: specifications	6	
		2.1.1	Dukoral (WC/rBS)	6	
		2.1.2	Shanchol	7	
		2.1.3	Characteristics of currently available vaccines	8	
	2.2	When	should OCV be used: suveillance, assessment		
		tool a	nd decision-making process	8	
		2.2.1	Surveillance, endemicity and seasonality	9	
		2.2.2	WHO decision-making tool for OCV use in		
			complex emergencies	9	
	2.3	WHO	recommendations on the use of OCV	10	
		2.3.1	Recommendations on the use of OCV in complex		
			emergency settings	10	
		2.3.2	Recommendations on the use of OCV to control		
			cholera outbreaks	11	
		2.3.3	Recommendations on the use of OCV in endemic		
			settings	11	
3.	Orga	nizing	and implementing a mass vaccination campaign	14	
	3.1	Regist	tration of the vaccine	15	
	3.2	Macro	oplanning – national level	15	
		3.2.1	Planning and supervision	15	
		3.2.2	Summary of activities at national level	16	
		3.2.3	Information, communication and social mobilization	19	
		3.2.4	Human resources	20	

	3.2.5 Logistics	23
	3.2.6 Budget	31
3.3	Microplanning – district level	32
	3.3.1 Planning and activites	32
	3.3.2 Immunization session	37
3.4	Common errors that may diminish campaign effectiveness	41
3.5	Mass vaccination campaigns linked to research studies	42
Annexe	s	45
Annex 1	Decision-making tool for the use of oral cholera	
	vaccine (OCV) in complex emergencies	47
Annex 2	Checklist for immunization campaign activities at	
	national level	55
Annex 3	Staff required and relevant job descriptions	57
Annex 4	Social mobilization and health education messages	62
Annex 5	Forms 1–5: tally sheets and summary tables	65
Annex 6	Team composition in different settings	72
Annex 7	Flowchart	74
Annex 8	Explanation and flow chart for control forms	75

References

1. Background

1.1 Introduction

About 1.8–2.8 million people die of diarrhoea every year, representing 3.7% of the 56 million deaths recorded globally. For children under the age of 5, the percentage of deaths due to diarrhoea reaches 15–19%. In low- and middle-income countries, diarrhoea is the second killer among communicable diseases after lower respiratory infections, the seventh when considering all causes of death. DALY calculation shows that diarrhoea ranks sixth among the causes of burden of disease, third among communicable diseases.

Epidemiological trends indicate that epidemic-prone diarrhoeal diseases have been rising in recent years. Massive outbreaks of cholera, a disease representing roughly 4.2% of all epidemic diarrhoea, now affect countries that had been free of the disease for decades. Cholera remains an important public health problem for many countries, and it is estimated that the disease kills between 75 000 and 120 000 people every year. Usuallyrecommended prevention and control measures are efficient, and WHO recommendations in this regard have not changed. However, they often cannot be put in place with sufficient timeliness and sustainability, which is why WHO is now considering the use of new tools that may contribute to lowering the effect of cholera on at-risk populations. Among them, safe and effective oral cholera vaccines (OCV) are now available, and WHO recommendations regulating their use have recently been issued and a 3-step decision-making tool developed for crisis situations, to guide policy-makers in their decision on whether to use OCV during complex emeraencies (1.2).

In this context, the Global Task Force on Cholera Control decided to issue practical information on the preparation and implementation of mass vaccination using OCV, intended for all (governments, institutions or NGOs) that might be involved in any phase of a mass vaccination campaign using OCV. This document aims to help organizers to prepare and implement campaigns in order to maximize benefits for the population.

- 1. Background
- 1.1 Introduction
- 1.2 Disease
- 1.3 Risk factors
- 1.4 Prevention and control
- 2. Cholera vaccines
- 2.1 Licensed OCV
- 2.2 When to use
- 2.3 WHO recommendations
- 3. Mass vaccination campaign
- 3.1 OCV Registration
- 3.2 Macroplanning
- 3.3 Microplanning
- 3.4 Common errors
- 3.5 Research studies

Information given here is essentially drawn from WHO's direct experience in the use of OCV.

1.2 The disease: causative agent, clinical manifestations, prevention

Cholera is an acute enteric infection caused by the ingestion of the bacteria *Vibrio cholerae* O1 or O139.¹ Transmission of the disease occurs through direct faecal-oral contamination or through ingestion of contaminated water or food. It is characterized in its most severe form by a sudden onset of acute watery diarrhoea with or without vomiting that may lead to death in a few hours as a result of severe dehydration, acidosis, circulatory collapse, hypoglycaemia in children and renal failure. Both children and adults may be affected. The extremely short incubation period – two hours to five days – enhances the potentially explosive pattern of outbreaks, so that the number of cases rises very quickly.

The infectious agent *V. cholerae* O1 is of two biotypes – classical and El Tor – that include three serotypes (Inaba, Ogawa and, rarely, Hikojima). However, the classical biotype has not been identified since the early 1990s. *V. cholerae* O139, first identified in Bangladesh in 1992 and currently present in various areas in South Asia, possesses the same virulence factors as O1, and creates a similar clinical picture. Reservoirs are human beings and environmental pockets – brackish water and estuaries – in association with copepods and zooplankton.

During the 19th century, cholera spread repeatedly from its original reservoir in the Ganges delta to the rest of the world, before receding back to South Asia. Six pandemics were recorded, killing millions of people across Europe, Africa and the Americas. The seventh pandemic, still ongoing, started in 1961 in South Asia, reached Africa in 1971 and the Americas in 1991. It is now considered that the disease is endemic in many countries, and that the pathogen causing cholera remains in the environment. It must therefore be controlled in order to limit its impact on populations.

About 75% of cholera cases are asymptomatic. Among those presenting symptoms, 80-90% develop acute watery diarrhoea, and 10-20% of these cases develop severe watery diarrhoea with vomiting. If untreated, the case-fatality rate may reach up to 40%; with proper treatment, it should remain below 1%.

The WHO standard case definition states that cholera should be suspected when:

¹ V. cholerae non-O1 non-O139 can cause mild diarrhoea but do not generate outbreaks.

- In an area where the disease is not known to be present, a patient aged 5 years or more¹ develops severe dehydration or dies from acute watery diarrhoea.
- 2. In an area where there is a cholera epidemic, a patient aged 5 years or more develops acute watery diarrhoea, with or without vomiting.

Diagnosis is confirmed by isolating *V. cholerae* O1 or O139 from faeces through laboratory testing. To ensure the quality of samples, Cary Blair transport medium should be used for transport and storage of rectal swabs. Laboratory testing is also required to determine antimicrobial resistance and should be performed regularly on a selected number of patients in the course of an outbreak to detect any change in antimicrobial susceptibility patterns.

1.3 Risk factors, seasonality and vulnerable groups

Cholera, a waterborne disease, is closely linked to inadequate environmental management. The absence or shortage of safe water and sufficient sanitation and, generally, poor environmental status are the main causes of spread of the disease. These factors are present in many places in the developing world, and even more acutely in overcrowded settings. Typical at-risk areas are periurban slums, where basic infrastructures are not available, as well as camps for internally displaced persons or refugees, where the minimum requirements² of clean water and sanitation are not met. The populations most affected are therefore those living in insalubrious conditions, where environmental safety is not ensured.

In the context of complex emergencies, it is important to stress that beliefs regarding cholera epidemics caused by dead bodies after disasters, whether natural or man-made, have been dismissed based on evidence (3,4) but uncontrolled rumours and panics are often rife. However, the consequence of a disaster – disruption of water and sanitation systems, massive displacement of populations to inadequate and overcrowded camps, etc. – may increase the risk of transmission, should the pathogen

预览已结束,完整报告链接和二

https://www.yunbaogao.cn/report/index/report?r